Exhibit 99.1 TransMedics Reports Third Quarter 2025 Financial Results Andover, Mass. – October 29, 2025 – TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2025. Recent Highlights Net income for the third quarter of 2025 was $24.3 million, or 17$4.2 million in the third quart ...